Edgewise Therapeutics (EWTX) said Wednesday that it priced an underwritten offering of about 9.9 million common shares at $20.13 per share for total proceeds of about $200 million.
Proceeds from the offering, which is set to close Thursday, will be used to support the potential US commercial launch of sevasemten in patients with Becker muscular dystrophy and advance sevasemten's phase 3 trial in Duchenne muscular dystrophy.
Remaining proceeds will also be used for the ongoing research and development programs, as well as for general corporate purposes, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。